<DOC>
	<DOC>NCT00235989</DOC>
	<brief_summary>The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.</brief_summary>
	<brief_title>Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of BetaseronÂ® to Treat Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc. Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Signed and dated statement of informed consent Completion of Protocol 307000A Negative serum pregnancy test results Agreement to adequate contraception, for female patients Pregnancy or lactation History of alcohol or drug abuse Inability to administer subcutaneous injections either by self or by caregiver Medical, psychiatric or other conditions that compromise the patient's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study Any significant change in the patient's medical condition after enrollment in Study 307000A which would have lead to his/her exclusion from participation that study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>interferon beta 1b</keyword>
	<keyword>Betaferon</keyword>
	<keyword>Betaseron</keyword>
</DOC>